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BACKGROUND
Antibiotic-resistant Neisseria gonorrhoeae has prompted the development of new thera-
pies. Zoliflodacin is a new antibiotic that inhibits DNA biosynthesis. In this multi-
center, phase 2 trial, zoliflodacin was evaluated for the treatment of uncomplicated 
gonorrhea.
METHODS
We randomly assigned eligible men and women who had signs or symptoms of un-
complicated urogenital gonorrhea or untreated urogenital gonorrhea or who had had 
sexual contact in the preceding 14 days with a person who had gonorrhea to receive 
a single oral dose of zoliflodacin (2 g or 3 g) or a single 500-mg intramuscular dose 
of ceftriaxone in a ratio of approximately 70:70:40. A test of cure occurred within 6±2 
days after treatment, followed by a safety visit 31±2 days after treatment. The pri-
mary efficacy outcome measure was the proportion of urogenital microbiologic cure 
in the microbiologic intention-to-treat (micro-ITT) population.
RESULTS
From November 2014 through December 2015, a total of 179 participants (167 men 
and 12 women) were enrolled. Among the 141 participants in the micro-ITT popula-
tion who could be evaluated, microbiologic cure at urogenital sites was documented 
in 55 of 57 (96%) who received 2 g of zoliflodacin, 54 of 56 (96%) who received 3 g 
of zoliflodacin, and 28 of 28 (100%) who received ceftriaxone. All rectal infections 
were cured in all 5 participants who received 2 g of zoliflodacin and all 7 who re-
ceived 3 g, and in all 3 participants in the group that received ceftriaxone. Pharyn-
geal infections were cured in 4 of 8 participants (50%), 9 of 11 participants (82%), 
and 4 of 4 participants (100%) in the groups that received 2 g of zoliflodacin, 3 g of 
zoliflodacin, and ceftriaxone, respectively. A total of 84 adverse events were reported: 
24 in the group that received 2 g of zoliflodacin, 37 in the group that received 3 g of 
zoliflodacin, and 23 in the group that received ceftriaxone. According to investiga-
tors, a total of 21 adverse events were thought to be related to zoliflodacin, and most 
such events were gastrointestinal.
CONCLUSIONS
The majority of uncomplicated urogenital and rectal gonococcal infections were suc-
cessfully treated with oral zoliflodacin, but this agent was less efficacious in the 
treatment of pharyngeal infections. (Funded by the National Institutes of Health and 
Entasis Therapeutics; ClinicalTrials.gov number, NCT02257918.)
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The incidence of gonorrhea in the United States increased by 67% from 2013 through 2017.1 Concomitantly, the anti-
microbial susceptibility of Neisseria gonorrhoeae 
has diminished.2,3 Decreased susceptibility and 
increased resistance to macrolides and cephalo-
sporins have been reported in the United States 
and around the world, and treatment failures 
have been noted.4-13 N. gonorrhoeae isolates that 
are resistant to the currently recommended regi-
men of ceftriaxone and azithromycin have also 
been reported.14-16
The Centers for Disease Control and Preven-
tion (CDC) revised treatment guidelines for 
gonorrhea three times between 2006 and 2012 
in response to both treatment failures and in-
creases in minimum inhibitory concentrations 
(MICs).17-21 Unfortunately, no highly reliable, 
orally administered, and affordable alternative 
antimicrobial agents with minimal side effects 
are currently available.
Zoliflodacin (also known as AZD0914 or 
ETX0914) is an investigational spiropyrimidine-
trione antimicrobial agent that has received 
“qualified infectious disease product” and sub-
sequent “fast track” designations from the Food 
and Drug Administration (FDA) for development 
solely as an oral treatment for gonococcal infec-
tions. The mechanism of action of zoliflodacin 
differs from currently available therapies in that 
it inhibits microbial biosynthesis by arresting the 
cleaved covalent gyrase complex and the forma-
tion of fused circular DNA required for biosyn-
thesis.22 The effectiveness of this mechanism has 
been illustrated by the sensitivity of ciprofloxacin-
resistant and ceftriaxone-resistant N. gonorrhoeae 
and fluoroquinolone-resistant and vancomycin-
resistant Staphylococcus aureus isolates to zolifloda-
cin.23 Zoliflodacin is also active against Chlamydia 
trachomatis, Chlamydophila pneumonia, Mycoplasma 
genitalium, and ureaplasma species.23 In this multi-
center, randomized, open-label, phase 2 trial, we 
compared the efficacy and safety of a single dose 
of 2 g or 3 g of oral zoliflodacin with 500 mg of 
intramuscular ceftriaxone for the treatment of 
uncomplicated urogenital gonorrhea.
M ater i a l s a nd Me thods
Oversight
This trial was conducted with approvals from the 
FDA, the European Medicines Agency, and the 
institutional review boards at each site. An inde-
pendent data and safety monitoring board re-
viewed the safety data. Entasis Therapeutics 
provided the zolif lodacin, and the Division of 
Microbiology and Infectious Diseases (DMID) at 
the National Institutes of Health provided the 
trial design. The initial draft of the manuscript 
was written by the first author. No paid medical 
writers participated in manuscript preparation. 
All authors had access to the data and vouch for 
the accuracy and completeness of the data and 
the fidelity of the trial to the protocol, available 
with the full text of this article at NEJM.org.
Participating Sites and Eligibility
Eligible persons were enrolled at sexual health 
clinics in New Orleans, Seattle, and Indianapolis 
and in Birmingham, Alabama, and Durham, 
North Carolina. Men and nonpregnant women 
18 to 55 years of age were eligible to participate 
if they had signs and symptoms of urogenital 
gonorrhea, untreated urogenital gonorrhea, or 
sexual contact in the preceding 14 days with a 
person who had gonorrhea. Other inclusion cri-
teria were the ability to provide written informed 
consent, negative results on a urine pregnancy 
test, abstinence from sexual intercourse with or 
without condom use for 7 days after treatment, 
use of a contraceptive (if of child-bearing poten-
tial) for 30 days before and after treatment, and 
condom use with another contraceptive for 30 
days after treatment.
Exclusion criteria were complicated gonorrhea 
(as indicated by pelvic inflammatory disease, 
epididymitis, or other conditions), use of sys-
temic or intravaginal antibiotics or antiviral 
agents within 30 days before enrollment, known 
allergy to cephalosporin or penicillin, or known 
coinfection with chlamydia at the time of enroll-
ment. Initially, known infection with the human 
immunodeficiency virus (HIV) was a criterion for 
exclusion, but this criterion was later modified 
to apply only to HIV-infected persons who were 
receiving antiretroviral therapy to avoid poten-
tial drug interactions with zolif lodacin. Other 
criteria for exclusion from the trial are available 
in Table S1 in the Supplementary Appendix, avail-
able at NEJM.org.
Trial Design
Zoliflodacin is a powder formulated for oral sus-
pension. Suspensions were prepared by a central 
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pharmacy in doses of 2 g and 3 g and then 
shipped and stored frozen. After thawing, the 
suspension was administered under direct ob-
servation by trial investigators.
Participants were randomly assigned to receive 
single, oral doses of 2 g or 3 g of zoliflodacin or 
a single intramuscular dose of 500 mg of ceftri-
axone. This ceftriaxone dose (twice the dose 
recommended by the CDC) was used to meet 
the regulatory requirements of both the FDA and 
the European Medicines Agency and to corre-
spond with the recommended European dose.24-26
At enrollment, specimens were obtained from 
urethral, cervical, pharyngeal, and rectal sites 
for N. gonorrhoeae culture and nucleic acid ampli-
fication testing (NAAT). Adverse events were 
graded with the use of toxicity tables that were 
based on the DMID comprehensive toxicity tables 
(20NOV2013) and modified for this trial. Ad-
verse events were followed through the final 
safety visit at 31±2 days.
Participants with negative gonococcal cultures 
could not be evaluated for the efficacy of zoliflo-
dacin but were followed for safety. Participants 
who had persistent genital symptoms (clinical 
failure) or positive results from gonococcal cul-
tures of samples obtained at any anatomical site 
(microbiologic failure) at test-of-cure visits re-
ceived further treatment in accordance with the 
local standard of care. Participants who had 
positive test results for C. trachomatis on samples 
obtained at enrollment were also treated at the 
test-of-cure visit.
Randomization
After written informed consent was obtained 
and eligibility for participation was assessed, par-
ticipants were randomly assigned in a 70:70:40 
ratio to receive either 2 g or 3 g of zolif lodacin 
or 500 mg of ceftriaxone. We used a permuted-
block randomization scheme stratified according 
to trial site and prepared at the Statistical and 
Data Coordinating Center at Emmes.
Estimation of Sample Size
The trial was designed to evaluate the safety of 
zoliflodacin and to inform the decision to pro-
ceed to a phase 3 trial. The enrollment goal was 
144 participants with positive baseline urethral 
or cervical cultures for N. gonorrhoeae. Assuming 
that 20% of potential participants would not be 
eligible, the target enrollment was 180 partici-
pants. An allocation ratio for the two zolifloda-
cin groups and the ceftriaxone group of 70:70:40 
was anticipated to result in at least 30 partici-
pants in the ceftriaxone group while maximiz-
ing the size of zoliflodacin groups for evaluation 
of safety.
Clinical and Microbiologic Procedures
Urethral, cervical, pharyngeal, and rectal swabs 
were collected for gonococcal culture and NAAT 
at enrollment, before administration of the trial 
drug. At the test-of-cure (day 6±2) and safety 
visits (day 31±2), repeat cultures and swabs for 
NAAT were obtained from all anatomical sites 
regardless of the participant’s history of sexual 
contact or baseline culture results at enrollment. 
NAAT was performed at local laboratories or at 
the Infectious Diseases Laboratory at the Univer-
sity of Alabama at Birmingham (UAB) with the 
use of Aptima Combo 2 (Hologic).
For culture, modified Thayer–Martin agar 
plates were inoculated and immediately placed in 
a carbon-dioxide–enriched environment before 
transport to local laboratories. Plates were read 
at 24, 48, and 72 hours after inoculation. Colo-
nies containing oxidase-positive, gram-negative 
diplococci were presumed to be N. gonorrhoeae. 
Isolates were frozen and shipped to the UAB 
laboratory, where the identification of neisseria, 
hemophilus, moraxella, and related bacteria was 
confirmed with the use of the Remel RapID NH 
System.
Agar dilution was used to determine bacte-
rial susceptibilities to zoliflodacin, azithromycin, 
cefixime, ceftriaxone, ciprofloxacin, penicillin, 
and spectinomycin. MIC breakpoints were de-
fined in accordance with the criteria of the 
Clinical and Laboratory Standards Institute for 
all drugs with the exception of azithromycin, 
zoliflodacin, and ceftriaxone.27 Lower MIC break-
points of 2.0 μg per milliliter and 0.5 μg per 
milliliter were used for azithromycin and zoli-
flodacin, respectively. For ceftriaxone, the lower 
breakpoint of 0.125 μg per milliliter was used, 
as defined by the Gonococcal Isolate Surveil-
lance Project.
Outcome and Efficacy Measures
The primary efficacy measure (microbiologic cure) 
was the proportion of participants with uro-
genital infection who had conversion from a 
positive baseline N. gonorrhoeae culture to a nega-
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tive culture at the test-of-cure visit. The primary 
outcome measure of safety was the proportion 
of participants reporting adverse events and 
serious adverse events related to the trial drug 
through the third visit.
Secondary efficacy outcome measures includ-
ed the proportion of participants with pharyn-
geal or rectal microbiologic cure; the proportion 
with negative results for N. gonorrhoeae on NAAT 
from swabs obtained from urethral, cervical, rec-
tal, or pharyngeal sites; the proportion of par-
ticipants with clinical cure (resolution of signs 
and symptoms of gonococcal infection); and 
MICs of N. gonorrhoeae against zoliflodacin and 
ceftriaxone at baseline and test of cure.
Analysis Populations
The microbiologic intention-to-treat (micro-ITT) 
population included all participants with gonor-
rhea at urethral or cervical sites who underwent 
randomization at enrollment. The outcome for 
participants who did not return for test-of-cure 
visits was classified as treatment failure. Partici-
pants with negative cultures for N. gonorrhoeae 
from urethral or cervical sites at enrollment 
were excluded from the micro-ITT analysis. Par-
ticipants with negative cultures for N. gonorrhoeae 
at rectal or pharyngeal sites at enrollment were 
excluded from the micro-ITT population for cor-
responding analyses for secondary efficacy end 
points.
The per-protocol efficacy population included 
participants in the micro-ITT population who 
met all criteria for inclusion, did not have con-
comitant infection other than chlamydia or bacte-
rial vaginosis, did not receive any other systemic 
antibiotic before test of cure, and returned for a 
test-of-cure visit within the window of 6±2 days.
Statistical Analysis
Primary and secondary efficacy end points were 
assessed in the micro-ITT populations and were 
repeated as secondary analyses in the per-proto-
col population. Point estimates for treatment-
group-specific proportions and difference in 
proportions between the zoliflodacin and ceftri-
axone groups with corresponding 95% confi-
dence intervals were calculated. All P values and 
confidence intervals are two-sided. Additional 
descriptive analyses for primary and secondary 
efficacy outcomes were performed according to 
treatment group. MIC distributions were sum-
marized for each treatment group and anatomi-
cal site at baseline and test-of-cure visits. Median, 
90th percentile, and range of MICs are reported. 
Adverse events were summarized in accordance 
with the Medical Dictionary for Regulatory Activities 
(MedDRA) version 18, preferred term and system 
organ class. The proportion of participants with 
and the exact 95% confidence interval for ad-
verse events were computed in aggregate and in 
accordance with MedDRA categories. Serious 
adverse events were reported in accordance with 
MedDRA coding; the dates of treatment, onset, 
and resolution; severity; relatedness; and out-
comes. Hematologic, hepatic, and renal labora-
tory results related to safety were assessed at 
enrollment and at test-of-cure and safety visits 
and were then summarized according to grade 
and treatment group. Standard summary sta-
tistics, including means and 95% confidence 
intervals, were computed. All statistical tests 
used 95% confidence intervals for binomial 
proportions, and differences in binomial propor-
tions were computed with the use of Clopper–
Pearson confidence limits.28 Analyses were 
conducted with SAS software, version 9.3 (SAS 
Institute).
R esult s
Characteristics of the Participants
Between November 2014 and December 2015, we 
screened 181 persons; 179 persons (167 men and 
12 women) underwent randomization and were 
treated (Fig. 1 and Table 1). Four HIV-infected 
participants were enrolled. Thirty-eight partici-
pants were excluded from the efficacy analysis 
owing to negative urethral or cervical gonococ-
cal cultures. Among the remaining 141 partici-
pants, 28 received 500 mg of ceftriaxone, 57 re-
ceived 2 g of zoliflodacin, and 56 received 3 g of 
zoliflodacin. Participants in the micro-ITT popu-
lations who could be evaluated included 141 
with positive urethral or cervical cultures, 23 with 
positive pharyngeal cultures, and 15 with posi-
tive rectal cultures. Participants in the per-proto-
col population who could be evaluated included 
117 with positive urethral cultures, 19 with posi-
tive pharyngeal cultures, and 13 with positive 
rectal cultures. All 179 participants completed 
the test-of-cure visit.
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Figure 1. Screening, Randomization, and Treatment.
The phrase “out of window of TOC [test of cure]” refers to a participant who returned outside the time frame of 6±2 days 
specified in the protocol. Micro-ITT denotes microbiologic intention to treat.
180 Underwent randomization
72 Were assigned to zoliflodacin, 2 g
67 Were assigned to zoliflodacin, 3 g
41 Were assigned to ceftriaxone, 500 mg
181 Participants were screened for eligibility
1 Had known allergy to cephalosporin
or penicillin antibiotics
179 Were included in the safety analysis population
72 Received zoliflodacin, 2 g
67 Received zoliflodacin, 3 g
40 Received ceftriaxone, 500 mg
1 Was excluded from safety analyses
(1 underwent randomization
but was not treated)
38 Were excluded from efficacy analyses 
owing to absence of positive result 
for urogenital Neisseria gonorrhoeae
at baseline
164 Were excluded from efficacy analyses
owing to absence of positive result
 for rectal N. gonorrhoeae
at baseline
141 Were in the micro-ITT urethral–
cervical population
57 Received zoliflodacin, 2 g
56 Received zoliflodacin, 3 g
28 Received ceftriaxone, 500 mg
23 Were in the micro-ITT pharyngeal 
population
8 Received zoliflodacin, 2 g
11 Received zoliflodacin, 3 g
4 Received ceftriaxone, 500 mg
15 Were in the micro-ITT rectal 
population
5 Received zoliflodacin, 2 g
7 Received zoliflodacin, 3 g
3 Received ceftriaxone, 500 mg
156 Were excluded from efficacy analyses
owing to absence of positive result
for pharyngeal N. gonorrhoeae
at baseline
24 Were excluded from per-protocol
analyses
17 Were out of window of TOC visit
1 Had concomitant infection
5 Had unprotected sexual activity 
≤7 days before or after receiving 
drug
1 Had side effects ≤30 min after
receiving drug
4 Were excluded from per-protocol
analyses
3 Were out of window of TOC visit
1 Had unprotected sexual activity 
≤7 days before or after receiving 
drug
2 Were excluded from per-protocol
analyses
1 Was out of window of TOC visit
1 Had concomitant infection
117 Were included in per-protocol
urethral–cervical population
49 Received zoliflodacin, 2 g
47 Received zoliflodacin, 3 g
21 Received ceftriaxone, 500 mg
19 Were included in per-protocol
pharyngeal population
6 Received zoliflodacin, 2 g
9 Received zoliflodacin, 3 g
4 Received ceftriaxone, 500 mg
13 Were included in per-protocol
rectal population
4 Received zoliflodacin, 2 g
6 Received zoliflodacin, 3 g
3 Received ceftriaxone, 500 mg
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Efficacy
At enrollment, 179 gonococcal infections were 
detected; these infections occurred in the ure-
thra, cervix, rectum, or pharynx. Microbiologic 
cure rates are presented according to anatomical 
site and treatment group in Table 2.
In the micro-ITT population, urogenital infec-
tions were cured in 55 of 57 participants (96%) 
in the group that received 2 g of zoliflodacin, 54 
of 56 participants (96%) in the group that re-
ceived 3 g of zoliflodacin, and 28 of 28 partici-
pants (100%) in the group that received 500 mg 
of ceftriaxone. In the per-protocol analyses, 48 of 
49 (98%), 47 of 47 (100%), and 21 of 21 (100%) 
of the participants in these respective groups 
had microbiologic cure. All rectal infections in 
all groups were cured. Pharyngeal gonorrhea 
was cured in 4 of 8 patients (50%) in the group 
that received 2 g of zoliflodacin and 9 of 11 
patients (82%) in the group that received 3 g of 
zoliflodacin. All four pharyngeal infections in the 
ceftriaxone group were cured (Table 2). In 3 HIV-
infected participants, N. gonorrhoeae was isolated 
only from urogenital sites, and these infections 
were cured.
Clinical Cure
In the micro-ITT population, among participants 
with signs and symptoms of N. gonorrhoeae infec-
tion at baseline, cure occurred in 52 of 57 partici-
pants (91%; 95% confidence interval [CI], 80 to 
97) in the group that received 2 g of zoliflodacin, 
Characteristic
University of 
Washington 
(N = 66)
Louisiana State 
University 
(N = 46)
Indiana 
University 
(N = 34)
University of 
Alabama 
(N = 22)
University of 
North Carolina 
(N = 12)
All Sites 
(N = 180)
Age
Mean 29.7±8.3 28.4±8.1 30.2±10.1 25.8±5.1 27.5±6.3 28.8±8.2
Median (IQR) 27 (19–53) 27 (18–53) 27 (18–53) 26 (19–40) 27 (18–42) 27 (18–53)
Sex — no. (%)
Male 64 (97) 46 (100) 34 (100) 13 (59) 10 (83) 167 (93)
Female† 2 (3) 0 0 9 (41) 2 (17) 13 (7)
Race — no. (%)
Black 15 (23) 34 (74) 26 (76) 22 (100) 10 (83) 107 (59)
White 42 (64) 10 (22) 5 (15) 0 1 (8) 58 (32)
Other, multiracial,  
or unknown‡
9 (14) 2 (4) 3 (9) 0 1 (8) 15 (8)
Ethnicity — no. (%)
Non-Hispanic 59 (89) 44 (96) 33 (97) 22 (100) 9 (75) 167 (93)
Hispanic 7 (11) 2 (4) 1 (3) 0 3 (25) 13 (7)
Sexual partner of male 
participants — 
no. (%)
Women only 13 (20) 30 (65) 26 (76) 13 (100) 8 (80) 90 (54)
Men only 45 (70) 13 (28) 6 (18) 0 2 (20) 66 (40)
Men and women 6 (9) 3 (7) 2 (6) 0 0 11 (7)
*  Plus–minus values are means ±SD. The denominators for percentages are based on the number of participants enrolled, with the exception 
of the sexual partner summaries, and represent the number of men or women enrolled in the trial for each therapy. Percentages may not to-
tal 100 because of rounding. IQR denotes interquartile range.
†  One woman was randomly assigned to a trial group and was subsequently found to be pregnant and thus was not treated. Among the 12 
women in the trial who underwent randomization and received treatment (7% of the total population), all 12 reported having sex with men.
‡  The category of “other, multiracial, or unknown” included 9 participants who were multiracial, 3 who were Asian, 1 who was an American 
Indian–Alaskan Native, 1 who was a Hawaiian–Pacific Islander, and 1 whose racial identity was unknown. Race and ethnic group were re-
ported by the participants.
Table 1. Selected Baseline Characteristics of Participants According to Trial Site.*
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46 of 49 participants (94%; 95% CI, 83 to 99%) 
in the group that received 3 g of zolif lodacin, 
and 26 of 27 participants (96%; 95% CI, 81 to 
100) in the group that received ceftriaxone. 
Clinical cure rates were similar in the per-proto-
col population.
Clearance of N. gonorrhoeae Nucleic Acid  
at Test of Cure
As assessed on NAAT, nucleic acid clearance oc-
curred in the micro-ITT population in 48 of 57 
participants (84%; 95% CI, 72 to 93) in the 
group that received 2 g of zoliflodacin, 42 of 52 
participants (81%; 95% CI, 67 to 90) in the 
group that received 3 g of zoliflodacin, and 25 
of 28 participants (89%; 95% CI, 71 to 98) in the 
group that received ceftriaxone. All participants 
with rectal gonorrhea detected on NAAT at enroll-
ment had nucleic acid clearance at the test-of-
cure visit. Nucleic acid clearance at test of cure 
was lowest in the pharynx, in 2 of 8 participants 
(25%) in the group that received 2 g of zoliflo-
dacin, 6 of 11 (55%) in the group that received 3 g 
of zolif lodacin, and 2 of 4 (50%) in the group 
that received ceftriaxone. Findings were similar 
in the per-protocol population.
Safety and Adverse Events
A total of 84 adverse events (24 in the group that 
received 2 g of zoliflodacin, 37 in the group that 
received 3 g of zoliflodacin, and 23 in the ceftri-
axone group) were reported by 59 participants 
(33%). The events included 11 moderate and 
1 serious adverse event, a nonfatal gunshot wound 
considered by the investigators to be unrelated to 
zoliflodacin (Table 3, and Table S2 in the Sup-
plementary Appendix). A total of 21 participants 
reported adverse events that investigators as-
sessed as being related to zoliflodacin; most 
such events were gastrointestinal and self-limit-
ing (5 events occurred in the group that received 
2 g of zoliflodacin and 8 events occurred in the 
group that received 3 g of zoliflodacin).
Antimicrobial Susceptibility Testing
No isolate at baseline or test of cure had MICs 
of zoliflodacin that were above the breakpoint 
(Tables S3 and S4 in the Supplementary Appen-
dix). Baseline isolate MICs at or above break-
points were noted for azithromycin, penicillin, 
and ciprofloxacin in the micro-ITT population. 
Among a total of 140 baseline urethral or cervi-
cal isolates for which there were results for MICs, 
24 (17%), 16 (11%), and 3 (2%) had MICs at or 
above the breakpoint for penicillin, ciprofloxacin, 
and azithromycin, respectively (Table S3 in the 
Supplementary Appendix). Among 14 baseline 
rectal isolates for which there were MIC results, 
2 (14%) had MICs at or above the breakpoint for 
penicillin. Among 23 baseline pharyngeal iso-
lates for which there were MIC results, 9 (39%), 
5 (22%), and 1 (4%) isolates had MICs at or above 
the breakpoint for penicillin, ciprofloxacin, and 
azithromycin, respectively. (Table 4 summarizes 
Population, Site,  
and Treatment
Confirmed  
Infections Cures
Microbiologic  
Cure
number % (95% CI)
Micro-ITT
Urethra or cervix
Zoliflodacin, 2 g 57 55 96 (88–100)
Zoliflodacin, 3 g 56 54 96 (88–100)
Ceftriaxone, 500 mg 28 28 100 (88–100)
Rectum
Zoliflodacin, 2 g  5  5 100 (48–100)
Zoliflodacin, 3 g  7  7 100 (59–100)
Ceftriaxone 500 mg  3  3 100 (29–100)
Pharynx
Zoliflodacin, 2 g  8  4 50 (16–84)
Zoliflodacin, 3 g 11  9 82 (48–98)
Ceftriaxone, 500 mg  4  4 100 (40–100)
Per protocol
Urethra or cervix
Zoliflodacin, 2 g 49 48 98 (89–100)
Zoliflodacin, 3 g 47 47 100 (92–100)
Ceftriaxone, 500 mg 21 21 100 (84–100)
Rectum
Zoliflodacin, 2 g  4  4 100 (40–100)
Zoliflodacin, 3 g  6  6 100 (54–100)
Ceftriaxone, 500 mg  3  3 100 (29–100)
Pharynx
Zoliflodacin, 2 g  6  4 67 (22–96)
Zoliflodacin, 3 g  9  7 78 (40–97)
Ceftriaxone, 500 mg  4  4 100 (40–100)
Table 2. Microbiologic Cure Rates at Test-of-Cure Visit — Micro-ITT  
and Per-Protocol Populations.
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the antimicrobial susceptibility of isolates accord-
ing to anatomical site.)
Among participants in whom there was micro-
biologic treatment failure, test-of-cure MICs were 
at or above the breakpoints for penicillin and 
ciprofloxacin (Table S4 in the Supplementary 
Appendix). Among the four cases of urethral or 
cervical infection for which there were MIC re-
sults, two isolates had MICs at or above the 
breakpoint for penicillin and one isolate had an 
MIC that was at or above the breakpoint for 
ciprofloxacin. Among participants in whom ther-
apy failed, there were no statistically significant 
changes in gonococcal pretreatment or post-
treatment MICs. The MIC for one pharyngeal 
isolate in a participant treated with ceftriaxone 
increased from 0.001 μg per milliliter at base-
line to 0.004 μg per milliliter at the test-of-cure 
visit, but the MIC did not reach the breakpoint.
There was no statistically significant differ-
ence between heterosexual participants and men 
who had sex with men with respect to the sus-
ceptibility of N. gonorrhoeae isolates to zolifloda-
cin at baseline or test of cure. A difference in 
susceptibility to azithromycin between these 
groups was noted (Figs. S1, S2, and S3 in the 
Supplementary Appendix).
Discussion
Zoliflodacin was effective in treating gonococcal 
urogenital and rectal infections. In the micro-ITT 
population, 96% of infected participants in the 
group that received a single oral dose of 2 g of 
zolif lodacin and in the group that received 3 g 
of zoliflodacin had microbiologic cure at urogeni-
tal sites. Although there were few participants 
with rectal infections, all had microbiologic cure. 
The efficacy of zolif lodacin was lower among 
participants with pharyngeal infections than 
among those with urogenital and rectal infec-
tions.
Zoliflodacin was not as effective as ceftriaxone 
in treating pharyngeal gonorrhea, which is gen-
erally more difficult to treat than urethral, cervi-
cal, or rectal gonorrhea. Currently, this limita-
tion has not curtailed recommendations for the 
use of drugs such as spectinomycin or f luoro-
quinolones for the treatment of gonorrhea.29-31 
In previous studies, pharyngeal isolates obtained 
from participants in whom treatment was not 
successful did not show antibiotic resistance or T
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meaningful change in antimicrobial susceptibility 
after treatment,29,31 as we observed in this trial. 
Thus, it has been speculated that poor drug pene-
tration into pharyngeal tissue may be responsi-
ble for most pharyngeal treatment failures rather 
than reinfection or resistant organisms.29
The traditional criterion for a recommenda-
tion of antibiotics for uncomplicated urogenital 
gonorrhea is a cure rate of more than 95%, with 
the lower boundary of the confidence interval 
greater than 95%.32 To be recommended as an 
alternative, the cure rate must be higher than 
95%, with the lower boundary of the confidence 
interval higher than 90%.32 Although the cure 
rates for 2 g of zoliflodacin, 3 g of zoliflodacin, 
and 500 mg of ceftriaxone met the point-estimate 
criteria for efficacy at the urogenital and rectal 
sites, only ceftriaxone met that criterion for the 
pharyngeal site. In our trial, the criteria for the 
lower boundaries of the confidence intervals were 
not met by either zoliflodacin or ceftriaxone for 
any anatomical site.
Microbiologic cure was defined on the basis of 
negative gonococcal cultures instead of NAATs. 
Regulatory agencies have preferred culture over 
NAAT for the assessment of cure because of the 
concern that residual nucleic acids from dead 
organisms may remain after successful therapy. 
Therefore, an NAAT obtained at a test-of-cure 
visit may result in false positive results and an 
inability to determine microbiologic cure.
The most common adverse events associated 
with zoliflodacin were gastrointestinal in nature. 
Although this trial did not involve a head-to-
head comparison, there appear to be fewer gas-
trointestinal effects with zoliflodacin than with 
other antibiotics currently recommended for un-
complicated gonorrhea.33-35 Larger, more detailed 
studies are needed to define this aspect of the 
side-effect profile of zoliflodacin.
The limitations of our trial include low en-
rollment of women and participants with rectal 
infections, as noted in other trials of drugs for 
the treatment of gonorrhea conducted within the 
past few years.34,35 The enrollment of women in 
trials of new drugs for the treatment of gonor-
rhea is challenging because of exclusions related 
to the use of contraceptives. Although there were 
few cases of rectal gonorrhea in our trial, all 
were successfully treated. This trial evaluated a 
single drug to allow the necessary comparative 
evaluation of efficacy, side-effect profile, and 
Specimen and 
Antimicrobial Drug
MIC  
Breakpoint
MIC50 
(μg/ml)
MIC90 
(μg/ml)
Range 
(μg/ml)
Proportion  
at or above  
MIC Breakpoint
no./total no. (%)
Urethra or cervix —  
140 isolates
Zoliflodacin ≥0.5 0.093 0.250 0.008–0.250 0/140
Azithromycin ≥2 0.250 1.000 0.060–4.000 3/140 (2)
Ceftriaxone ≥0.125 0.008 0.015 0.001–0.060 0/140
Rectum — 14 isolates
Zoliflodacin ≥0.5 0.060 0.250 0.008–0.250 0/14
Azithromycin ≥2 0.250 1.000 0.125–1.000 0/14
Ceftriaxone ≥0.125 0.006 0.008 0.001–0.015 0/14
Pharynx — 23 isolates
Zoliflodacin ≥0.5 0.125 0.250 0.008–0.250 0/23
Azithromycin ≥2 0.500 1.000 0.060–2.000 1/23
Ceftriaxone ≥0.125 0.008 0.030 0.001–0.060 0/23
*  Values for minimum inhibitory concentration (MIC) were defined as the lowest concentration of the antibiotic at which 
90% (MIC90) and 50% (MIC50) of the isolates were inhibited.
Table 4. Comparison of Zoliflodacin with Currently Recommended Antimicrobials for the Treatment of Gonorrhea 
According to Site of Infection (Micro-ITT Population).*
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safety. However, current U.S. and European guide-
lines recommend dual therapy for gonorrhea — 
theoretically, to slow the development of anti-
microbial resistance and to treat concomitant 
chlamydial infection. Should the development of 
zoliflodacin for gonorrhea therapy be pursued, 
its use in combination with another active agent 
would probably be the goal.
N. gonorrhoeae has developed resistance to every 
class of antibiotic recommended for treatment, 
which now includes cephalosporins and macro-
lides. Reports of multidrug-resistant N. gonorrhoeae 
and the possibility of untreatable gonorrhea 
underscore the need for the development of new 
antimicrobial agents. This phase 2 trial creates 
equipoise for larger, more definitive studies of 
zoliflodacin.
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